Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
ICU Medical reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to digest the actual numbers.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-07 | +$3.48 (+2.91%) | $2.76 (2.31%) | +$3.36 (+2.73%) | $7.30 (5.93%) |
| 2026-02-19 | -$1.89 (-1.25%) | $4.54 (2.99%) | +$7.29 (+4.87%) | $17.37 (11.60%) |
| 2025-11-06 | +$2.29 (+1.80%) | $5.81 (4.56%) | +$10.49 (+8.09%) | $13.48 (10.40%) |
| 2025-08-07 | +$3.02 (+2.38%) | $4.99 (3.93%) | -$17.06 (-13.13%) | $15.71 (12.09%) |
| 2025-05-08 | +$8.37 (+6.22%) | $9.80 (7.29%) | -$4.57 (-3.20%) | $13.03 (9.12%) |
| 2025-02-27 | -$4.52 (-2.93%) | $5.34 (3.46%) | -$3.42 (-2.28%) | $15.15 (10.12%) |
| 2024-11-12 | -$0.26 (-0.15%) | $4.88 (2.74%) | -$3.20 (-1.80%) | $21.81 (12.25%) |
| 2024-08-07 | -$1.89 (-1.53%) | $6.03 (4.88%) | +$29.56 (+24.27%) | $22.55 (18.52%) |
| Avg Abs Move | 2.40% | 4.02% | 7.55% | 11.25% |
ICUI's post-earnings price behavior shows significant volatility, with an average absolute Day +1 move of 7.55% and an average Day +1 range of 11.25%. The stock has demonstrated dramatic swings in both directions, including a 24.27% surge following the August 2024 report and a 13.13% decline after August 2025 earnings.
The most recent report in May 2026 produced a relatively modest 2.73% Day +1 gain with a 5.93% range, well below historical averages. However, the preceding three reports all generated Day +1 moves exceeding 4.8%, with ranges consistently above 10%. This pattern suggests investors should prepare for substantial price movement regardless of whether the company beats or misses estimates — the stock's reaction appears driven more by guidance and forward commentary than the headline beat itself.
| Metric | Value |
|---|---|
| Expiration Date | 08/21/26 (DTE 16) |
| Expected Move | $0.00 (0.00%) |
| Expected Range | $166.36 to $166.36 |
| Implied Volatility | 55.95% |
The options market is pricing zero expected move for the August 21 expiration, which appears to be a data anomaly given ICUI's historical volatility around earnings. Based on the stock's 7.55% average absolute Day +1 move and 11.25% average Day +1 range, investors should anticipate significantly more movement than the options data suggests.
Analysts maintain a bullish stance on ICU Medical with an average rating of 4.63 (between Buy and Strong Buy) and a mean price target of $176.43, implying 6.0% upside from the current $166.40 price. The consensus includes 6 Strong Buy ratings, 1 Moderate Buy, and 1 Hold, with no sell ratings among the 8 analysts covering the stock.
However, sentiment has deteriorated over the past month, with the average recommendation slipping from 4.88 as one analyst downgraded from Strong Buy. The rating count shifted from 7 Strong Buys and 1 Moderate Buy a month ago to the current 6-1-1 distribution, suggesting some profit-taking or valuation concerns at current levels.
The price target range spans from a low of $163.00 to a high of $200.00, with the bull case implying 20.2% upside if ICUI can demonstrate sustained margin expansion and market share gains. The relatively tight clustering of estimates — with the high target just 22.7% above the low — indicates analysts are largely aligned on the company's near-term prospects, even as one has grown more cautious on valuation.
ICU Medical enters earnings with strong technical momentum, as the Barchart Technical Opinion registers an 88% Buy signal, unchanged from last week but significantly improved from 40% Buy a month ago. This strengthening reflects the stock's sustained advance above key moving averages.
Timeframe Analysis:
Trend Characteristics: The Strong and Strengthening trend environment indicates ICUI is building positive momentum at an opportune time, with technical conditions supportive heading into earnings.
The stock trades at $166.40, positioned above its 10-day ($165.29), 20-day ($161.30), 50-day ($149.66), 100-day ($137.37), and 200-day ($140.00) moving averages, though it has pulled back slightly below the 5-day average of $169.64. This alignment above all major long-term moving averages provides technical support, while the minor pullback from the 5-day average suggests some near-term consolidation after the recent rally.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $169.64 | 50-Day MA | $149.66 |
| 10-Day MA | $165.29 | 100-Day MA | $137.37 |
| 20-Day MA | $161.30 | 200-Day MA | $140.00 |
The stock is trading just 2.1% below its 52-week high of $162.85 (note: current price of $166.40 is actually above this level, indicating a new high), demonstrating exceptional relative strength. Key support now sits at the 10-day moving average of $165.29, with deeper support at the rising 20-day line of $161.30. The technical setup is decidedly supportive for earnings, with the stock in a confirmed uptrend and momentum indicators aligned positively across all timeframes. However, the proximity to recent highs means the stock has less cushion for disappointment, and any guidance concerns could trigger profit-taking from the strong year-to-date advance of nearly 19% from the 200-day moving average.